Sign in

    Chi Wen Chin

    Vice President and Equity Research Analyst at TD Cowen

    Chi Wen Chin is a Vice President and Equity Research Analyst at TD Cowen, specializing in technology and consumer sectors with a focus on major public companies such as Meta Platforms, Confluent, Western Digital, Old Dominion Freight Line, and Lam Research. Recognized for diligent analysis and market insight, Chin has contributed to investment calls that have achieved notable success rates, including price target adjustments that have aligned closely with subsequent stock performance. He began his career in equity research after earning relevant securities licenses and registered with FINRA, joining TD Cowen in the early 2020s following earlier positions in financial services. Chin holds professional credentials as a registered broker at TD Securities (USA) LLC, bringing expertise in stock ratings and buy- or hold-side recommendations.

    Chi Wen Chin's questions to COMPASS Pathways (CMPS) leadership

    Chi Wen Chin's questions to COMPASS Pathways (CMPS) leadership • Q1 2025

    Question

    Chi Wen Chin of TD Cowen, on for Ritu Baral, asked for details on the manufacturing supply chain, the potential impact of pharma tariffs, any FDA inspections, and a timeline for establishing a U.S. manufacturing site.

    Answer

    CEO Kabir Nath stated that the product is currently made in the U.K., and plans are already underway to add a U.S. manufacturing site for commercial supply, though no specific timeline was given. CFO Teri Loxam added that manufacturing is a straightforward process and not a high-risk area. Mr. Nath also noted that potential tariffs could be factored into future pricing.

    Ask Fintool Equity Research AI

    Chi Wen Chin's questions to ACADIA PHARMACEUTICALS (ACAD) leadership

    Chi Wen Chin's questions to ACADIA PHARMACEUTICALS (ACAD) leadership • Q4 2024

    Question

    Chi Wen Chin, on for Ritu Baral, asked about DAYBUE utilization, including the percentage of patients titrated to the recommended dose, the drivers behind improved discontinuation rates, and strategies for the expanded sales force.

    Answer

    CCO Tom Garner reported that patients on DAYBUE are at approximately 70% of the target label dose on average. The 15% improvement in discontinuations was attributed to enhanced patient education and support from the Acadia Connect team. He noted that with 60% of patients now on therapy for over a year, this growing, stable base is a key focus for the expanded field force to support and drive continued utilization.

    Ask Fintool Equity Research AI